A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
Open Access
- 6 July 2022
- journal article
- research article
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-8
Abstract
Purpose. RECOVERY, ACTT-1, and ACTT-2 trials have demonstrated that utilization of dexamethasone, remdesivir, or a combination of remdesivir with baricitinib leads to mortality benefit and faster time to recovery, respectively. However, no studies have investigated the benefit of triple therapy of dexamethasone, remdesivir, and baricitinib. We investigate the benefits of triple therapy compared to dual therapy of dexamethasone with remdesivir in patients with severe COVID-19 on HFNC. Materials and Methods. A retrospective data analysis was performed on patients with severe COVID-19 requiring HFNC and evaluated for hospital discharge status, requirement of mechanical ventilation, length of stay, and days on HFNC. Results. Among 191 patients with severe COVID-19, 81 patients received dexamethasone, remdesivir, and baricitinib. Patients receiving triple therapy had a significant survival benefit (HR 0.52; ). Treatment with triple therapy vs. dual therapy also trended towards less requirement of mechanical ventilation (OR 0.66; ). There was no significant change in length of stay (mean 13.74 vs. 13.31; ) or days on HFNC (mean 8.95 vs. 7.28 days, ). Conclusions. The use of dexamethasone, remdesivir, and baricitinib in patients with severe COVID-19 requiring HFNC was associated with a significant survival benefit in comparison to dual therapy of dexamethasone with remdesivir.Keywords
This publication has 23 references indexed in Scilit:
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaNew England Journal of Medicine, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research, 2019
- The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysisCritical Care, 2019
- Cytokine release syndromeJournal for ImmunoTherapy of Cancer, 2018
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activationJournal of Allergy and Clinical Immunology, 2013
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012